0001291656-16-000013.txt : 20160317
0001291656-16-000013.hdr.sgml : 20160317
20160317120004
ACCESSION NUMBER: 0001291656-16-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160315
FILED AS OF DATE: 20160317
DATE AS OF CHANGE: 20160317
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun
CENTRAL INDEX KEY: 0001291656
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 161511829
MAIL ADDRESS:
STREET 1: SCICLONE PHARMACEUTICALS, INC.
STREET 2: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2016-03-15
0
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001291656
Cheung Wilson Wai-Shun
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
0
1
0
0
CFO & Senior VP, Finance
Incentive Stock Option (right to buy)
9.12
2016-03-15
4
A
0
11131.0
0.0
A
2026-03-15
Common Stock
11131
11131
D
Non-Qualified Stock Option (right to buy)
9.12
2016-03-15
4
A
0
72869.0
0.0
A
2026-03-15
Common Stock
72869
72869
D
Restricted Stock Unit
2016-03-15
4
A
0
12000.0
0.0
A
Common Stock
12000
199000
D
Granted under the Issuer's 2015 Equity Incentive Plan.
25% of such shares vest one year from the date of grant and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
Vesting for such RSUs will occur 25% on March 15, 2017, 25% on March 15, 2018, 25% on March 15, 2019, and 25% on March 15, 2020, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
/s/ Wilson W. Cheung
2016-03-17